CBMG, a Cellular Biomedicine Group, was officially listed on NASDAQ in 2014, becoming the only nasdaq-listed Chinese cell to treat biotech companies. West to than man of keen perception, accurate judgment and strong r&d strength, take the lead in building the international leading diversified cell therapy biomedical product development platform, development of the immune cells used in the treatment of cancer treatment products and stem cell therapy products for the treatment of degenerative diseases.
Companies adhering to the "save lives After new life "concept, brought together a large number of excellent technical personnel and management team, stem cells and immune treatment through the development and the introduction of the world's most advanced biological treatment technology, and the world's large hospitals and research institutions research innovation platform of scientific research cooperation, comprehensive build a solid platform for the translational medicine, strive to become the international leading innovative cell bio-pharmaceutical companies in China, provide the safe and effective for patients with global immune treatment technologies and products.
CBMG currently has 0 opportunities.
Select the following options: